挑战、进展与机遇：丝状病毒医学应对措施研讨会会议记录
Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.
作者信息
Hirschberg Rona, Ward Lucy A, Kilgore Nicole, Kurnat Rebecca, Schiltz Helen, Albrecht Mark T, Christopher George W, Nuzum Ed
机构信息
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Medical Countermeasure Systems, Department of Defense, Ft. Detrick, Frederick, MD 21702, USA.
出版信息
Viruses. 2014 Jul 9;6(7):2673-97. doi: 10.3390/v6072673.
Abstract
On August 22-23, 2013, agencies within the United States Department of Defense (DoD) and the Department of Health and Human Services (HHS) sponsored the Filovirus Medical Countermeasures (MCMs) Workshop as an extension of the activities of the Filovirus Animal Non-clinical Group (FANG). The FANG is a federally-recognized multi-Agency group established in 2011 to coordinate and facilitate U.S. government (USG) efforts to develop filovirus MCMs. The workshop brought together government, academic and industry experts to consider the needs for filovirus MCMs and evaluate the status of the product development pipeline. This report summarizes speaker presentations and highlights progress and challenges remaining in the field.
摘要
2013年8月22日至23日，美国国防部（DoD）和卫生与公众服务部（HHS）下属机构主办了丝状病毒医学应对措施（MCMs）研讨会，作为丝状病毒动物非临床小组（FANG）活动的延伸。FANG是一个2011年成立的联邦认可的多机构小组，旨在协调和推动美国政府（USG）开发丝状病毒MCMs的工作。该研讨会汇聚了政府、学术和行业专家，以探讨丝状病毒MCMs的需求并评估产品研发进程的状况。本报告总结了发言人的演讲内容，并突出了该领域尚存的进展和挑战。
相似文献
1
Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.挑战、进展与机遇：丝状病毒医学应对措施研讨会会议记录
Viruses. 2014 Jul 9;6(7):2673-97. doi: 10.3390/v6072673.
2
An interagency collaboration to facilitate development of filovirus medical countermeasures.机构间合作促进丝状病毒医疗对策的开发。
Viruses. 2012 Oct 19;4(10):2312-6. doi: 10.3390/v4102312.
3
Filovirus vaccines: what challenges are left?丝状病毒疫苗：还存在哪些挑战？
Expert Rev Vaccines. 2010 Jan;9(1):5-8. doi: 10.1586/erv.09.150.
4
Filovirus vaccines.丝状病毒疫苗
Hum Vaccin. 2011 Jun;7(6):701-11. doi: 10.4161/hv.7.6.15398. Epub 2011 Jun 1.
5
Characterization of a putative filovirus vaccine: virus-like particles.一种假定的丝状病毒疫苗的特性：病毒样颗粒。
Virol Sin. 2013 Apr;28(2):65-70. doi: 10.1007/s12250-013-3306-9. Epub 2013 Feb 6.
6
A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs.一种单载体、单次注射的三价丝状病毒疫苗：远交豚鼠的概念验证研究
J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S384-8. doi: 10.1093/infdis/jiv126. Epub 2015 May 9.
7
Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine.丝状病毒的出现与疫苗研发：旅行医学中医疗从业者的视角。
Travel Med Infect Dis. 2011 May;9(3):126-34. doi: 10.1016/j.tmaid.2010.05.003. Epub 2010 Jun 26.
8
The structural basis for filovirus neutralization by monoclonal antibodies.丝状病毒中和单克隆抗体的结构基础。
Curr Opin Immunol. 2018 Aug;53:196-202. doi: 10.1016/j.coi.2018.05.001. Epub 2018 Jun 22.
9
Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage.设计和测试针对细胞毒性 T 淋巴细胞表位覆盖范围进行优化的广泛保护性丝状病毒疫苗。
PLoS One. 2012;7(10):e44769. doi: 10.1371/journal.pone.0044769. Epub 2012 Oct 3.
10
Immune response to filovirus infections.对丝状病毒感染的免疫反应。
Curr Top Microbiol Immunol. 1999;235:205-17. doi: 10.1007/978-3-642-59949-1_11.
引用本文的文献
1
A Review of Nonhuman Primate Models of Rift Valley Fever Virus Infection: Progress, Challenge Strains, and Future Directions.裂谷热病毒感染的非人灵长类动物模型综述：进展、挑战菌株及未来方向
Pathogens. 2024 Oct 1;13(10):856. doi: 10.3390/pathogens13100856.
2
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.非人灵长类动物到人类的免疫桥接研究表明，Ad26.ZEBOV-MVA-BN-Filo疫苗对埃博拉具有保护作用。
NPJ Vaccines. 2022 Nov 30;7(1):156. doi: 10.1038/s41541-022-00564-z.
3
Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates.非人灵长类动物中丝状病毒疗效研究的保护免疫相关因素
Vaccines (Basel). 2022 Aug 18;10(8):1338. doi: 10.3390/vaccines10081338.
4
Adapting Simon's Two-Stage Design for Efficient Screening of Filovirus Vaccines in Non-Human Primates.采用西蒙两阶段设计在非人灵长类动物中高效筛选丝状病毒疫苗
Vaccines (Basel). 2022 Jul 29;10(8):1216. doi: 10.3390/vaccines10081216.
5
Comparison of Aerosol Stability of Different Variants of Ebola Virus and Marburg Virus and Virulence of Aerosolised Ebola Virus in an Immune-Deficient Mouse.不同变异型埃博拉病毒和马尔堡病毒的气溶胶稳定性比较及免疫缺陷小鼠中气溶胶化埃博拉病毒的毒力。
Viruses. 2022 Apr 9;14(4):780. doi: 10.3390/v14040780.
6
Opportunities for Refinement of Non-Human Primate Vaccine Studies.改进非人灵长类动物疫苗研究的机会。
Vaccines (Basel). 2021 Mar 19;9(3):284. doi: 10.3390/vaccines9030284.
7
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate.通过非人灵长类动物与人之间的免疫桥接来推断一种埃博拉病毒候选疫苗的保护效果。
NPJ Vaccines. 2020 Dec 17;5(1):112. doi: 10.1038/s41541-020-00261-9.
8
Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus.从扎伊尔埃博拉病毒中吸取的经验教训，以帮助满足针对苏丹埃博拉病毒和马尔堡病毒疫苗的迫切需求。
Hum Vaccin Immunother. 2020 Nov 1;16(11):2855-2860. doi: 10.1080/21645515.2020.1741313. Epub 2020 Apr 10.
9
Approach to Strain Selection and the Propagation of Viral Stocks for Venezuelan Equine Encephalitis Virus Vaccine Efficacy Testing under the Animal Rule.在动物法则下进行委内瑞拉马脑炎病毒疫苗效力测试时病毒株的选择及病毒种毒繁殖方法
Viruses. 2019 Aug 31;11(9):807. doi: 10.3390/v11090807.
10
Safeguarding against Ebola: Vaccines and therapeutics to be stockpiled for future outbreaks.防范埃博拉：储备疫苗和治疗方法以应对未来疫情。
PLoS Negl Trop Dis. 2018 Apr 5;12(4):e0006275. doi: 10.1371/journal.pntd.0006275. eCollection 2018 Apr.
本文引用的文献
1
Standards for sequencing viral genomes in the era of high-throughput sequencing.高通量测序时代病毒基因组测序标准
mBio. 2014 Jun 17;5(3):e01360-14. doi: 10.1128/mBio.01360-14.
2
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.将以ChAd63和MVA ME-TRAP进行的初免-加强免疫的免疫原性从无疟疾人群转化至疟疾流行地区人群。
Mol Ther. 2014 Nov;22(11):1992-2003. doi: 10.1038/mt.2014.109. Epub 2014 Jun 16.
3
Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.4型和7型腺病毒疫苗接种或4型腺病毒呼吸道感染引发的针对非人腺病毒疫苗载体的交叉反应性抗体反应极小。
Clin Vaccine Immunol. 2014 May;21(5):783-6. doi: 10.1128/CVI.00011-14. Epub 2014 Mar 12.
4
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.新型广谱核苷类似物 BCX4430 对丝状病毒病的防护作用。
Nature. 2014 Apr 17;508(7496):402-5. doi: 10.1038/nature13027. Epub 2014 Mar 2.
5
Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb.用ZMAb治疗受感染的非人灵长类动物后对埃博拉病毒感染的持续保护作用。
Sci Rep. 2013 Nov 28;3:3365. doi: 10.1038/srep03365.
6
mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms.当在检测到病毒血症和症状后给予单克隆抗体和腺载体 IFN-α 治疗时，可挽救感染埃博拉病毒的非人灵长类动物。
Sci Transl Med. 2013 Oct 16;5(207):207ra143. doi: 10.1126/scitranslmed.3006605.
7
Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.用 MB-003 单克隆抗体鸡尾酒疗法治疗恒河猴的埃博拉病毒感染。
Sci Transl Med. 2013 Aug 21;5(199):199ra113. doi: 10.1126/scitranslmed.3006608.
8
Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.在啮齿动物中模拟对腺病毒的预先存在的免疫力：基于重组5型腺病毒的埃博拉疫苗成功研发的免疫要求
Mol Pharm. 2013 Sep 3;10(9):3342-55. doi: 10.1021/mp4001316. Epub 2013 Aug 19.
9
A comparative high-throughput screening protocol to identify entry inhibitors of enveloped viruses.一种用于鉴定包膜病毒进入抑制剂的比较性高通量筛选方案。
J Biomol Screen. 2014 Jan;19(1):100-7. doi: 10.1177/1087057113494405. Epub 2013 Jul 2.
10
Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.委内瑞拉马脑炎病毒复制子颗粒疫苗可保护非人灵长类动物免受埃博拉病毒的肌肉内和呼吸道挑战。
J Virol. 2013 May;87(9):4952-64. doi: 10.1128/JVI.03361-12. Epub 2013 Feb 13.
Zotero 插件